公司资料
Amgen Inc. 股价、新闻与催化剂
- 股票代码:
- AMGN
- 交易所:
- NASDAQ
- 行业:
- Generics, Biopharma, Oncology, Immunotherapy
- 所在地:
- Thousand Oaks, California
股票表现
419.38 USD (+1.00%)
收盘价
最后更新: 2026年8月17日
177B USD
市值
股价为何变动
As of Aug 17, 2026, AMGN closed up 1.00% at $419.38. No new same-company headline was identified in the current news window.
公司概览
业务概览
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
所在地与行业分类
Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is a global biotechnology company with substantial U.S. and international revenue exposure. Its profile is shaped by scale, commercialization, and a broad therapeutic footprint.
商业模式特征
Amgen uses commercial cash flow to fund R&D and business development across both mature and newer franchises. Investors tend to watch launch execution, regulatory events, and portfolio refresh rather than pure clinical-stage binary risk.
生物医药行业定位
Amgen is one of the best-known large-cap biotech names and usually trades with less single-asset dependence than smaller peers. It still moves on pipeline, regulatory, and label milestones, but its diversified base makes the story more durable.
未来催化剂
- Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
- 01
- 02
Management commentary keeps pipeline priorities in focus
- 03
Investors watch oncology and cardiometabolic launch cadence
- 04
Regulatory calendar keeps Amgen in the spotlight
- 05
Pipeline updates reinforce the commercial-stage narrative
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。